Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges

SIMPLE SUMMARY: Here we list the benefits and disadvantages of using bispecific T cell engagers (BTCEs) for the treatment of multiple myeloma (MM). We summarize the mechanism of action; the various targets used for BTCE therapy for MM such as BCMA, CD38, FcRH5, CD19, and CD138; and novel strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhallak, Kinan, Sun, Jennifer, Jeske, Amanda, Park, Chaelee, Yavner, Jessica, Bash, Hannah, Lubben, Berit, Adebayo, Ola, Khaskiah, Ayah, Azab, Abdel Kareem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228067/
https://www.ncbi.nlm.nih.gov/pubmed/34201007
http://dx.doi.org/10.3390/cancers13122853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228067/
https://www.ncbi.nlm.nih.gov/pubmed/34201007
http://dx.doi.org/10.3390/cancers13122853

Ejemplares similares